➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Last Updated: August 1, 2021

DrugPatentWatch Database Preview

Details for Patent: 9,000,021

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,000,021 protect, and when does it expire?

Patent 9,000,021 protects BENDEKA and is included in one NDA.

This patent has thirty-two patent family members in fifteen countries.

Summary for Patent: 9,000,021

Title:	Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration
Abstract:	Methods of treating bendamustine responsive conditions in patients having fluid and/or sodium intake restrictions are disclosed. The methods include identifying patients having such restrictions and in need of bendamustine, and then administering thereto a bendamustine-containing composition in a volume of about 120 ml or less intravenously over a period of about 15 minutes or less. The smaller volumes and reduced sodium load as compared to currently known methods of treatment minimize cardiac and/or renal stress in patients having diseases such as congestive heart failure or renal disease.
Inventor(s):	Sundaram; Srikanth (Somerset, NJ), Tarriff; Scott L. (Mahwah, NJ)
Assignee:	Eagle Pharmaceuticals, Inc. (Woodcliff Lake, NJ)
Application Number:	13/838,267
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,000,021
Patent Claim Types: see list of patent claims	Use; Composition; Delivery;

Drugs Protected by US Patent 9,000,021

Subscribe to access the full database, or Try it Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Eagle Pharms	BENDEKA	bendamustine hydrochloride	SOLUTION;IV (INFUSION)	208194-001	Dec 7, 2015		RX	Yes	Yes	⤷ Try it Free	⤷ Try it Free				FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND/OR NON-HODGKINS LYMPHOMA	⤷ Try it Free
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 9,000,021

Subscribe to access the full database, or Try it Free
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2867295	⤷ Try it Free
Canada	2867343	⤷ Try it Free
China	104271135	⤷ Try it Free
China	104302291	⤷ Try it Free
China	107157988	⤷ Try it Free
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow

Merck

Boehringer Ingelheim

McKinsey

Johnson and Johnson

AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.